Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 6:47 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2449–2472 of 6,233 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Part 1 Clear all

Conditions: Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Esophageal Squamous Cell Carcinoma, Squamous Cell Carcinoma of Head and Neck
Interventions: QEQ278; Biological
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 4
States / cities: Los Angeles, California • Fort Myers, Florida • Boston, Massachusetts

Conditions: Overweight, Overweight and Obesity, Overweight or Obesity, Obesity, Obese
Interventions: Counseling, Text Messages, Phone calls, Self-monitoring tools; Behavioral
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 21 Years and older
Enrollment: 1,889 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Carcinoma, Ductal, Breast, Breast Cancer Female, Breast Neoplasm, Breast Cancer, Metastatic Breast Cancer, Advanced Breast Cancer, Stage IV Breast Cancer
Interventions: G1T48, Palbociclib; Drug
Lead sponsor: G1 Therapeutics, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 6
States / cities: Beverly Hills, California • Stanford, California • Chicago, Illinois + 3 more

Conditions: Surgery, Stomach Cancer, Pancreas Cancer, Bile Duct Cancer, Liver Cancer, Peritoneal Cancer
Interventions: Music-assisted relaxation and imagery (MARI); Behavioral
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 50 Years to 80 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Eye Diseases, Macular Degeneration, Retinal Diseases, Retinal Degeneration, Neovascularization, Pathologic
Interventions: OPT-302, Lucentis™; Drug
Lead sponsor: Opthea Limited; Industry
Eligibility: 50 Years and older
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 14
States / cities: Phoenix, Arizona • Beverly Hills, California • Sacramento, California + 11 more

Conditions: Lung Cancer, Non-small Cell Lung Cancer
Interventions: PET/CT and BH PET/CT; Procedure
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: New York, New York

Conditions: Metastatic Pancreatic Ductal Adenocarcinoma, PDAC
Interventions: Telisotuzumab adizutecan, Fluorouracil, Folinic acid/ Leucovorina, Oxaliplatin, Irinotecan; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 900 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 9
States / cities: New Haven, Connecticut • Chicago, Illinois • Zion, Illinois + 6 more

Conditions: RSV Infection
Interventions: EDP-938, Tacrolimus, Dabigatran, Rosuvastatin, Midazolam; Drug
Lead sponsor: Enanta Pharmaceuticals, Inc; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 89 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Diabetes Mellitus, Type 2, Diabetes Complications
Interventions: Diabetes Tune-Up Group; Behavioral
Lead sponsor: Indiana University; Other
Eligibility: 21 Years and older · Female only
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Type 2 Diabetes
Interventions: AZD0186, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 31 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Glendale, California

Conditions: Breast Cancer
Interventions: Letrozole, Abemaciclib; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 2
States / cities: Dallas, Texas

Conditions: Cystic Fibrosis, Pancreatic Insufficiency
Interventions: GLP-1, GIP; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2026
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Healthy
Interventions: Placebo, SRK-439; Drug
Lead sponsor: Scholar Rock, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 76 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Angelman Syndrome
Interventions: Alogabat; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 5 Years to 17 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 6
States / cities: Chicago, Illinois • Boston, Massachusetts • New York, New York + 3 more

Conditions: Hepatocellular Carcinoma
Interventions: AZD9793 Intravenous (IV) monotherapy, AZD9793 Subcutaneous (SC) monotherapy; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 304 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 7
States / cities: La Jolla, California • Los Angeles, California • Baltimore, Maryland + 4 more

Conditions: Locally Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
Interventions: Biopsy Procedure, Biospecimen Collection, Cisplatin, Computed Tomography, Gemcitabine, Gemcitabine Hydrochloride, Magnetic Resonance Imaging, Veliparib; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2027
U.S. locations: 9
States / cities: Chicago, Illinois • Harvey, Illinois • Ann Arbor, Michigan + 6 more

Conditions: Solid Tumor, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer
Interventions: DS-3939a, Pembrolizumab, Carboplatin, Pemetrexed, DS-1103a; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 7
States / cities: Fayetteville, Arkansas • Los Angeles, California • Tampa, Florida + 4 more

Conditions: Apical Periodontitis, Pulp Disease, Dental
Interventions: Iron oxide nanoparticles treatment Ferumoxytol/H2O2, NaOCl, NaCl, supplementary irrigation; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL)
Interventions: Blinatumomab, Pembrolizumab; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 3
States / cities: La Jolla, California • Charleston, South Carolina • Greenville, South Carolina

Conditions: Food Insecurity
Interventions: Produce prescription, Nutrition education; Behavioral
Lead sponsor: Cornell University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 4
States / cities: Buffalo, New York

Conditions: Sickle Cell Disease
Interventions: Alemtuzumab, Total Body Irradiation, Sirolimus; Drug · Radiation
Lead sponsor: Kathleen Dorritie; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Sinus Node Dysfunction
Interventions: Treadmill/Bicycle exercise testing; Diagnostic Test
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 100 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: New York, New York

Conditions: Radius Fracture Distal, Pain, Postoperative
Interventions: Acupuncture; Device
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years to 64 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Glioblastoma (GBM), Newly Diagnosed Glioblastoma, GBM, Glioblastoma Multiforme (GBM), Glioma, Central Nervous System Diseases, Brain Cancer
Interventions: silevertinib in combination with temozolomide, temozolomide (TMZ); Drug
Lead sponsor: Black Diamond Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 162 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 39
States / cities: Birmingham, Alabama • Springdale, Arkansas • La Jolla, California + 34 more

Search by objective public record fields.

A Study to Investigate the Safety and Tolerability of Intravenous QEQ278 in Patients With Advanced Solid Tumors

Taxi ROADmAP (Realizing Optimization Around Diet And Physical Activity)

G1T48, an Oral SERD, Alone and in Combination With Palbociclib in ER-Positive, HER2-Negative Advanced Breast Cancer

TRANScriptional Pathways Of Surgical Pain Modulated by Music Therapy Exposure (TRANSPOSE)

Study Evaluating the Safety, Pharmacokinetics and Pharmacodynamics of OPT-302 With or Without Lucentis™ in Patients With Wet AMD

Breathing Synchronized PET/CT Scans for the Detection of Malignant Lung & Liver Lesions and Assessment of Tumor Glycolysis

A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan in Combination With Fluorouracil, Folinic Acid, and Oxaliplatin (FOLFOX) Compared to Standard of Care in Adult Participants With First-Line Metastatic Pancreatic Ductal Adenocarcinoma

Drug-Drug Interaction Study Between EDP-938, Tacrolimus, Dabigatran, Rosuvastatin and Midazolam in Healthy Subjects

Electronic Diabetes Tune-Up Group (eDTU) for African Americans

A Study to Assess Safety, Tolerability, and Pharmacokinetics of AZD0186

Single Cell Immune and Non-immune Correlates of Response to Neoadjuvant Abemaciclib

Beta-cell Response to Incretin Hormones in Cystic Fibrosis

A Single- and Multiple-Ascending Dose Study of SRK-439 in Healthy Adults

A Study to Investigate the Pharmacokinetics (PK) and Safety and to Provide Proof of Mechanism of Alogabat in Children and Adolescents Aged 5-17 Years With Angelman Syndrome (AS) With Deletion Genotype.

First in Human Study to Evaluate AZD9793 in Participants With Advanced or Metastatic Solid Tumours

Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer

A Study of DS-3939a in Participants With Solid Tumors

A New Clinical Use of Ferumoxytol Nanoparticles: An Antibiofilm Treatment

Study Investigating the Safety and Efficacy of Blinatumomab in Combination With Pembrolizumab in Adults With Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL)

FreshStart for Health Study

Stem Cell Transplant in Patients With Severe Sickle Cell Disease

Effectiveness of Closed Loop Stimulation (CLS) With His Bundle Lead Placement

Auricular Acupuncture As Part Of A Multimodal Regimen After Distal Radius Open Reduction and Internal Fixation

Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII